T. Jacobs

发表

Bayesian knowledge integration for an in vitro–in vivo correlation model

M. Gasparini, M. Ursino, J. Biewenga, 2018, Biometrical journal. Biometrische Zeitschrift.

A proposal for a new PhD level curriculum on quantitative methods for drug development

W. Brannath, X. Paoletti, M. Posch, 2018, Pharmaceutical statistics.

Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential

W. Drinkenburg, H. Huysmans, W. H. I. M. Drinkenburg, 2014, Neuropharmacology.

Optimal Designs for Non-Compartmental Analysis of Pharmacokinetic Studies

H. Geys, T. Jaki, T. Jacobs, 2018, Statistics in Biopharmaceutical Research.

Bayesian sequential integrationwithin a preclinical PK-PDmodeling framework: Potential challenges and opportunities

C. Faes, H. Geys, J. Serroyen, 2018 .

Methods for Non-Compartmental Pharmacokinetic Analysis With Observations Below the Limit of Quantification

H. Geys, T. Jaki, T. Jacobs, 2020 .

In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants

O. Lenz, L. Vijgen, T. Verbinnen, 2015, Antimicrobial Agents and Chemotherapy.

Bayesian sequential integrationwithin a preclinical PK-PDmodeling framework: Lessons learned

H. Geys, J. Serroyen, T. Jacobs, 2019 .

Modeling in-vitro functional assay of allosteric modulators

H. Lavreysen, T. Jacobs, I. Biesmans, 2013 .

JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate.

D. Moechars, K. Kusakabe, L. Leclercq, 2021, Journal of medicinal chemistry.

Reporter gene expression from LTR-circles as tool to identify HIV-1 integrase inhibitors.

R. Clayton, M. Van Loock, B. Malcolm, 2013, Journal of virological methods.

Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned

Moreno Ursino, Thomas Jaki, Helena Geys, 2019, Pharmaceutical statistics.

Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.

H. Ceulemans, J. Neyts, O. Lenz, 2012, The Journal of antimicrobial chemotherapy.

A Bayesian K‐PD model for synergy: A case study

Christel Faes, Helena Geys, Tom Jacobs, 2018, Pharmaceutical statistics.

Bayesian pooling versus sequential integration of small preclinical trials: a comparison within linear and nonlinear modeling frameworks

Helena Geys, Tom Jacobs, Fabiola La Gamba, 2020, Journal of biopharmaceutical statistics.

Combined Models for Data from In Vitro–In Vivo Correlation Experiments

G. Molenberghs, L. Bijnens, T. Jacobs, 2008, Journal of biopharmaceutical statistics.

A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI-PHOSPHO-TAU ANTIBODY JNJ-63733657 IN HEALTHY SUBJECTS

M. Mercken, T. Malia, W. Galpern, 2019, Alzheimer's & Dementia.

Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593‐606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873

W. Brannath, X. Paoletti, M. Posch, 2019, Pharmaceutical statistics.

Non-linear mixed-effects modeling for complex biopharmaceutical data

Tom Jacobs, T. Jacobs, 2009 .

A Latent Pharmacokinetic Time Profile to Model Dose-Response Survival Data

Geert Molenberghs, Luc Bijnens, Tom Jacobs, 2010, Journal of biopharmaceutical statistics.